Non interventional post-authorisation safety study (PASS) to define the incidence of and potential risk factors for procedure-related neurological adverse events (AE) in patients undergoing ultrasound guided foam sclerotherapy (UGFS) for the treatment of lower limb varicose veins (VV) using Fibrovein 3% and 1% (sodium tetradecyl sulphate, STS, injection) incorporating a drug utilisation study (Fibrovein PASS)

15/01/2015
02/07/2024
EU PAS number:
EUPAS8260
Study
Finalised
Documents
Study protocol
Initial protocol
English (431.3 KB - PDF) View document
Study results
Study results
English (271.47 KB - PDF) View document
Study report
Study report
English (718.67 KB - PDF) View document
English (266.42 KB - PDF) View document
Other information
Study, other information
English (266.42 KB - PDF) View document